SITC 54199 is a residual 'not elsewhere specified' heading, meaning it should only be used after systematically ruling out all more specific pharmaceutical headings. Importers should document the classification analysis — identifying the product's composition, form, and intended use — and confirm that no more specific heading applies before defaulting to this category. Misclassification into a residual heading when a specific heading exists can trigger customs queries or penalties.

Pharmaceutical excipients used in drug manufacturing are generally subject to FDA oversight as drug components, and foreign manufacturers supplying excipients to US drug makers are expected to comply with applicable GMP standards. While excipients themselves may not always require a separate NDA, the facilities producing them can be subject to FDA inspection, and importers should ensure their suppliers maintain appropriate quality system documentation.